REVIEWS Moving from Basic Toward Systems Pharmacodynamic Models

Building upon many classical foundations of pharmacology, a diverse array of mechanistic pharmacokinetic-pharmacodynamic (PK/PD) models have emerged based on mechanisms of drug action and primary rate-limiting or turnover processes in physiology. An array of basic models can be extended to handle various complexities including tolerance and can readily be employed as building blocks in assembling enhanced PK/PD or small systems models. Our corticosteroid models demonstrate these concepts as well as elements of horizontal and vertical integration of molecular to whole-body processes. The potential advantages and challenges in moving PK/PD toward systems models are described. © 2013 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 102:2930-2940, 2013

[1]  Matthew M Riggs,et al.  A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. , 2010, Bone.

[2]  J. Mandema,et al.  Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. , 1995, The Journal of pharmacology and experimental therapeutics.

[3]  A. J. Clark The Rate of Action of Drugs on Cells , 1937 .

[4]  Richard R. Almon,et al.  Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis I: Mechanistic Disease Progression Model for the Time Course of Collagen-Induced Arthritis in Lewis Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.

[5]  P. Toutain,et al.  Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic/pharmacodynamic modeling approach. , 2000, The Journal of pharmacology and experimental therapeutics.

[6]  W. Jusko,et al.  Pharmacokinetics and Pharmacodynamics of PEGylated IFN-β 1a Following Subcutaneous Administration in Monkeys , 2004, Pharmaceutical Research.

[7]  G. Ferron,et al.  Pharmacodynamic Modeling of Pantoprazole's Irreversible Effect on Gastric Acid Secretion in Humans and Rats , 2001, Journal of clinical pharmacology.

[8]  William J. Jusko,et al.  Applications of minimal physiologically-based pharmacokinetic models , 2012, Journal of Pharmacokinetics and Pharmacodynamics.

[9]  R R Almon,et al.  Extracting Global System Dynamics of Corticosteroid Genomic Effects in Rat Liver , 2008, Journal of Pharmacology and Experimental Therapeutics.

[10]  W J Jusko,et al.  Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. , 1998, Journal of pharmaceutical sciences.

[11]  Gary An,et al.  Translational Systems Biology of Inflammation , 2008, PLoS Comput. Biol..

[12]  W J Jusko,et al.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects , 1994, Clinical pharmacology and therapeutics.

[13]  T Iga,et al.  Comparative pharmacodynamics of eight calcium channel blocking agents in Japanese essential hypertensive patients. , 1996, Biological & pharmaceutical bulletin.

[14]  Donald E. Mager,et al.  Comparison of Two Pharmacodynamic Transduction Models for the Analysis of Tumor Therapeutic Responses in Model Systems , 2010, The AAPS Journal.

[15]  M Danhof,et al.  Pharmacokinetic-pharmacodynamic modeling of the electroencephalographic effects of benzodiazepines. Correlation with receptor binding and anticonvulsant activity. , 1991, The Journal of pharmacology and experimental therapeutics.

[16]  Donald E. Mager,et al.  General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[17]  W. Jusko,et al.  Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin. , 2005, British journal of clinical pharmacology.

[18]  R. Ramakrishnan,et al.  Fifth-Generation Model for Corticosteroid Pharmacodynamics: Application to Steady-State Receptor Down-Regulation and Enzyme Induction Patterns During Seven-Day Continuous Infusion of Methylprednisolone in Rats , 2002, Journal of Pharmacokinetics and Pharmacodynamics.

[19]  R. Iyengar,et al.  Merging Systems Biology with Pharmacodynamics , 2012, Science Translational Medicine.

[20]  Terrence P. Kenakin,et al.  A Pharmacologic Analysis of Drug-Receptor Interaction , 1987 .

[21]  Onn Brandman,et al.  Feedback Loops Shape Cellular Signals in Space and Time , 2008, Science.

[22]  R. Furchgott,et al.  The pharmacology of vascular smooth muscle. , 1955, Pharmacological reviews.

[23]  G. An In silico experiments of existing and hypothetical cytokine-directed clinical trials using agent-based modeling* , 2004, Critical care medicine.

[24]  Lewis B. Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine , 1979 .

[25]  DE Mager,et al.  Development of Translational Pharmacokinetic–Pharmacodynamic Models , 2008, Clinical pharmacology and therapeutics.

[26]  W. Jusko,et al.  Physiologically based pharmacokinetic models for everolimus and sorafenib in mice , 2013, Cancer Chemotherapy and Pharmacology.

[27]  W. Jusko,et al.  Pharmacokinetic–Pharmacodynamic Modeling of Tolmetin Antinociceptive Effect in the Rat Using an Indirect Response Model: A Population Approach , 1998, Journal of Pharmacokinetics and Biopharmaceutics.

[28]  Varun Garg,et al.  Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[29]  W J Jusko,et al.  Pharmacodynamic modeling of time‐dependent transduction systems , 2001, Clinical pharmacology and therapeutics.

[30]  A. Hill,et al.  The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves , 1910 .

[31]  Joseph P. Balthasar,et al.  Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[32]  J. Black,et al.  Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.

[33]  Lawrence J Lesko,et al.  Quantitative disease, drug, and trial models. , 2009, Annual review of pharmacology and toxicology.

[34]  L. Lesko,et al.  Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans , 2000, Journal of clinical pharmacology.

[35]  W Ewy,et al.  Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.

[36]  John Anthony Bauer,et al.  Pharmacodynamic Models of Nitroglycerin-Induced Hemodynamic Tolerance in Experimental Heart Failure , 1994, Pharmaceutical Research.

[37]  Jianguo Zhi,et al.  Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due toPseudomonas aeruginosa , 1988, Journal of Pharmacokinetics and Biopharmaceutics.

[38]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[39]  Richard R Almon,et al.  Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis II: Mechanistic Pharmacodynamic Model for Dexamethasone Effects in Lewis Rats with Collagen-Induced Arthritis , 2008, Journal of Pharmacology and Experimental Therapeutics.

[40]  Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development , 1992 .

[41]  J. Wagner,et al.  Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. , 1968, Journal of theoretical biology.

[42]  C Garnett,et al.  Impact of Pharmacometric Reviews on New Drug Approval and Labeling Decisions—a Survey of 31 New Drug Applications Submitted Between 2005 and 2006 , 2007, Clinical pharmacology and therapeutics.

[43]  G Levy,et al.  Kinetics of pharmacologic effects , 1966, Clinical pharmacology and therapeutics.

[44]  Hoi-Kei Lon,et al.  Pharmacokinetic/pharmacodynamic modeling in inflammation. , 2012, Critical reviews in biomedical engineering.

[45]  W J Jusko,et al.  Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. , 1971, Journal of pharmaceutical sciences.

[46]  Yasuhiko Yamada,et al.  Parmacodynamic Analysis of Antiplatelet Effect of Aspirin in the Literature. Modeling Based on Inhibition of Cyclooxygenase in the Platelet and the Vessel Wall Endothelium. , 1996 .

[47]  Mats O Karlsson,et al.  Pharmacokinetic/pharmacodynamic modelling in oncological drug development. , 2005, Basic & clinical pharmacology & toxicology.

[48]  W J Jusko,et al.  Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. , 1998, Journal of pharmaceutical sciences.